-
ASCO China Focus | “Rebirth: I Want to Keep My Bladder”—Professor Yijun Shen Presents Phase II ReBirth Study on Stratified Bladder-Sparing Approaches After Neoadjuvant Immunochemotherapy
To live or to live well?” This Shakespearean dilemma continues to haunt many patients with bladder cancer. How to provide longer-lasting disease control while preserving the bladder through safer and more tolerable strategies has become a central challenge in urologic oncology. At the 2025 ASCO Annual Meeting, Professor Yijun Shen from Fudan University Shanghai Cancer…
-
Prof. Philip Kwong: New Strategies and Emerging Horizons in the Management of mHSPC
The “2025 Pujiang Prostate Cancer Academic Conference,” held from June 27 to 28 in Shanghai, was jointly organized with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Annual Conference of the Chinese Prostate Cancer Consortium (CPCC).…
-
Professor Dingwei Ye: The Three Dimensions of Surgical Treatment for Prostate Cancer — Skill Advancement, Technological Innovation, and Conceptual Reform | 2025 CACA Integrated Prostate Oncology Conference
At the “CACA Integrated Prostate Oncology Conference” held from June 14–15, numerous Chinese experts and scholars gathered under the theme “Winning Through Integration in Cancer Control” to engage in academic discussions on the latest CACA prostate cancer guideline updates, recent research advances, and multidisciplinary team (MDT) evaluations of complex cases. Professor Dingwei Ye from Fudan…
-
ASCO Expert Commentary | Professors Xuesong Li, Qi Tang, and Xiaoying Li: Addressing the Unique Challenges of UTUC in China—Disitamab Vedotin Paves the Way for a New Era in Adjuvant Therapy
Oncology Frontier – UroStream UTUC has a different pathogenesis compared to bladder cancer, and Chinese UTUC cases differ significantly from those in Western populations. Therefore, Western treatment paradigms cannot be…
-
Professor Jiwei Huang: The “Renji Experience” in Neoadjuvant Therapy for UTUC | CUDA 2025
The 2025 Annual Meeting of the Chinese Urological Association (CUDA), held from June 12 to 15 in the romantic city of Zhuhai, brought together leading experts under the theme “Healthy China, Urology First.” At the conference, Professor Jiwei Huang from Renji Hospital, Shanghai Jiao Tong University School of Medicine, delivered a compelling presentation on neoadjuvant…
Connecting Medical Expertise through Media
